Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Bristol-Myers Squibb
BMYHealthcareGenerated Aug 19, 2026, 09:18 PM UTC
BMY (Bristol-Myers Squibb) analytical snapshot. Revenue declined +0.2% YoY to $48.19B. 5-year revenue CAGR +0.8%; 10y CAGR +10.6%. Net margin at 14.64% (expanding ▲). Market cap $138.11B at $67.61 per share. Trailing P/E 19.54, P/S 2.87, P/B 6.19. EV/Operating income ≈ 46.44 (EV $172.25B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score 19 (data confidence 84%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 11, 2026. Latest quarterly report (10-Q) filed Jul 30, 2026. 12 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 11, 2026.
- Latest quarterly report (10-Q) filed Jul 30, 2026.
- 12 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Bristol-Myers Squibb; broad institutional reporting.
- Recent filers include SUMMIT SECURITIES GROUP, LLC, CLEAR STREET MARKETS LLC, FREMONT INVESTMENT ADVISORS INC.
- 14 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 6 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| SUMMIT SECURITIES GROUP, LLC | 13F-HR | May 9, 2019 |
| CLEAR STREET MARKETS LLC | 13F-HR | Apr 28, 2020 |
| FREMONT INVESTMENT ADVISORS INC | 13F-HR | Oct 22, 2001 |
| FREMONT INVESTMENT ADVISORS INC | 13F-HR | Jan 16, 2002 |
| Axiom Investment Management LLC | 13F-HR | Mar 16, 2021 |
| Date | Form | Description |
|---|---|---|
| Jul 30, 2026 | 8-K | 8-K |
| May 8, 2026 | 8-K | CURRENT REPORT |
| Apr 30, 2026 | 8-K | 8-K |
| Feb 5, 2026 | 8-K | 8-K |
| Jan 12, 2026 | 8-K | CURRENT REPORT |
| Nov 18, 2025 | 8-K | CURRENT REPORT |
| Nov 10, 2025 | 8-K | FORM 8-K |
| Nov 3, 2025 | 8-K | CURRENT REPORT |
SEC Filing Deep-Analysis
2 risk signal(s), 2 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 2 positive signal(s) versus 2 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- Earnings-cash flow divergence: Net income grew +178.8% while operating cash flow declined -6.8%. This divergence may indicate accrual-based earnings inflation — non-cash gains, aggressive revenue recognition, or working capital absorption. The accrual ratio (NI − OCF) is deteriorating.
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 5 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
- Operating cash flow exceeds net income: OCF is 2.01x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Gross margin expansion: Gross margin expanded +26.4%pp (from 37.4% to 63.8%), indicating improved pricing power, cost efficiency, or favorable product mix.
- R&D intensity declining: R&D as % of revenue fell from 23.1% to 20.6%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
- Endogenous analysis: 2 positive signal(s) versus 2 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 2 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- Ongoing high-severity risk language: Restatement of financial statements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $48.30B | $48.19B | $-106.0M | -0.2% |
| Gross profit | $18.07B | $30.75B | $12.68B | +70.2% |
| Operating income | $3.10B | $3.71B | $607.0M | +19.6% |
| Net income | $-8.95B | $7.05B | $16.00B | +178.8% |
| Operating cash flow | $15.19B | $14.16B | $-1.03B | -6.8% |
| Capex | $1.25B | $1.31B | $63.0M | +5.0% |
| Total assets | $92.60B | $90.04B | $-2.56B | -2.8% |
| Total liabilities | $76.22B | $71.53B | $-4.68B | -6.1% |
| Long-term debt | $49.43B | $44.83B | $-4.60B | -9.3% |
| Cash & equivalents | $10.35B | $10.21B | $-137.0M | -1.3% |
| Stockholders equity | $16.34B | $18.47B | $2.14B | +13.1% |
| Inventory | $2.56B | $2.69B | $133.0M | +5.2% |
| Accounts receivable | $9.01B | $9.59B | $580.0M | +6.4% |
| R&D expense | $11.16B | $9.95B | $-1.21B | -10.8% |
| SG&A expense | $8.41B | $7.27B | $-1.15B | -13.6% |
| Interest expense | $1.23B | $1.17B | $-66.0M | -5.4% |
| Type | Concepts |
|---|---|
| Added | AccountsAndOtherReceivablesNetCurrent, DebtInstrumentRepaidPrincipal |
| Removed | CommonStockParOrStatedValuePerShare, CommonStockSharesAuthorized, CommonStockSharesIssued, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit, DebtInstrumentCarryingAmount, DeferredFederalIncomeTaxExpenseBenefit, DeferredForeignIncomeTaxExpenseBenefit, DeferredIncomeTaxLiabilities |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Restatement of financial statements | high | 5 | 1 | Ongoing |
| Impairment charge | medium | 5 | 7 | Ongoing |
| Restructuring | medium | 5 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 2 | Ongoing |
| Related party transactions | low | 5 | 2 | Ongoing |
Fundamentals
Revenue declined +0.2% YoY to $48.19B. 5-year revenue CAGR +0.8%; 10y CAGR +10.6%. Net margin at 14.64% (expanding ▲).
- Revenue declined +0.2% YoY to $48.19B.
- 5-year revenue CAGR +0.8%; 10y CAGR +10.6%.
- Net margin at 14.64% (expanding ▲).
- Return on equity 38.19%, ROA 7.83%, ROIC 0.00%.
- Gross margin 0.00%, operating margin 0.00%.
- Free cash flow margin 26.65% ($12.85B).
- Net income up ▲ +178.8% YoY.
- Debt/equity 1.92, current ratio 1.53, net debt $34.14B.
- Asset turnover 0.55 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $48.30B | +7.3% | 0.00 | 0.00 | -18.53 | $13.94B | -54.78 |
| 2025 | $48.19B | -0.2% | 0.00 | 0.00 | 14.64 | $12.85B | 38.19 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Sep 30, 2024 | $11.89B | +8.4% | — | 10.18% |
| Mar 31, 2025 | $11.20B | -5.6% | -5.8% | 21.93% |
| Jun 30, 2025 | $12.27B | +0.6% | +9.5% | 10.68% |
| Sep 30, 2025 | $12.22B | +2.8% | -0.4% | 18.01% |
| Mar 31, 2026 | $11.49B | +2.6% | -6.0% | 23.30% |
| Jun 30, 2026 | $12.97B | +5.7% | +12.9% | 25.57% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $138.11B at $67.61 per share. Trailing P/E 19.54, P/S 2.87, P/B 6.19. EV/Operating income ≈ 46.44 (EV $172.25B).
- Market cap $138.11B at $67.61 per share.
Price & Technicals
Price $67.61 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 62.09.
- Price $67.61 — uptrend (above 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity 1.92 (moderate). Liquidity current ratio 1.53 (adequate).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite 19
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Bristol-Myers Squibb is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewMarket cap $138.11B at $67.61 per share..
Peer comparison
Defensive groupHow BMY stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 21 | Neutral |
| Bristol-Myers Squibb BMY● you | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Zoetis Inc. ZTS | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -5 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Walmart Inc. WMT | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |